Blarcamesine (ANAVEX®2-73)
Alzheimer’s Disease
Key Facts
About Anavex Life Sciences
Anavex Life Sciences is a clinical-stage biotech focused on developing oral therapeutics for central nervous system (CNS) disorders by targeting the sigma-1 receptor (SIGMAR1). Its lead asset, blarcamesine, has generated pivotal clinical data in Alzheimer's disease and holds Orphan Drug Designation for Rett syndrome, positioning it in multi-billion dollar markets with high unmet need. The company operates with a lean, virtual model, advancing a precision medicine platform that aims to modify disease pathology rather than just alleviate symptoms.
View full company profileAbout Anavex Life Sciences
Anavex Life Sciences is a clinical-stage biotech focused on developing oral therapeutics for central nervous system (CNS) disorders by targeting the sigma-1 receptor (SIGMAR1). Its lead asset, blarcamesine, has generated pivotal clinical data in Alzheimer's disease and holds Orphan Drug Designation for Rett syndrome, positioning it in multi-billion dollar markets with high unmet need. The company operates with a lean, virtual model, advancing a precision medicine platform that aims to modify disease pathology rather than just alleviate symptoms.
View full company profileAbout Anavex Life Sciences
Anavex Life Sciences is a clinical-stage biotech focused on developing oral therapeutics for central nervous system (CNS) disorders by targeting the sigma-1 receptor (SIGMAR1). Its lead asset, blarcamesine, has generated pivotal clinical data in Alzheimer's disease and holds Orphan Drug Designation for Rett syndrome, positioning it in multi-billion dollar markets with high unmet need. The company operates with a lean, virtual model, advancing a precision medicine platform that aims to modify disease pathology rather than just alleviate symptoms.
View full company profileAbout Anavex Life Sciences
Anavex Life Sciences is a clinical-stage biotech focused on developing oral therapeutics for central nervous system (CNS) disorders by targeting the sigma-1 receptor (SIGMAR1). Its lead asset, blarcamesine, has generated pivotal clinical data in Alzheimer's disease and holds Orphan Drug Designation for Rett syndrome, positioning it in multi-billion dollar markets with high unmet need. The company operates with a lean, virtual model, advancing a precision medicine platform that aims to modify disease pathology rather than just alleviate symptoms.
View full company profileTherapeutic Areas
Other Alzheimer’s Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| SPC-14 | Silo Pharma | Preclinical |
| Masitinib | AB Science | Phase 3 |
| Leronlimab | CytoDyn | Phase 1 |
| Alzheimer's Drug | Dawah Pharmaceuticals | Development |
| Alzheimer’s Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |